Compare CERS & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | TCMD |
|---|---|---|
| Founded | 1991 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.1M | 533.5M |
| IPO Year | 1996 | 2016 |
| Metric | CERS | TCMD |
|---|---|---|
| Price | $2.15 | $28.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 2.2M | 203.9K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | 17.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,326,000.00 | N/A |
| Revenue This Year | $19.95 | $11.60 |
| Revenue Next Year | $8.84 | $9.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.68 | N/A |
| 52 Week Low | $1.15 | $9.60 |
| 52 Week High | $3.47 | $37.77 |
| Indicator | CERS | TCMD |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 46.81 |
| Support Level | $1.89 | $27.03 |
| Resistance Level | $2.20 | $27.67 |
| Average True Range (ATR) | 0.18 | 1.11 |
| MACD | -0.09 | -0.23 |
| Stochastic Oscillator | 2.54 | 23.45 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.